ArticleIranian journal of pathology2022
Preoperative Neutrophil: Lymphocyte Ratio, Platelet: Lymphocyte Ratio, and C-Reactive Protein Levels Predictive Value in Determining the Severity of Breast Mass.
Article in Iranian journal of pathology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 6 citations in OpenAlex.
- Emerging biomarkers in breast fibroadenoma: implications for differential diagnosis, malignant transformation, and precision medicine.Molecular biology reports · 2026Review
- The evidence for the use of peripheral blood indices in the diagnosis of breast cancer.The Journal of international medical research · 2026Review
- Systemic Inflammatory and Hematological Profiles in Triple-Negative Breast Cancer: A Study from a Senegalese Cohort.Diagnostics (Basel, Switzerland) · 2026Article
- Importance of hematological and inflammatory markers in the localization of gastric cancer.World journal of gastrointestinal oncology · 2025Article
- A comprehensive bioinformatic evaluation of the NTRK family's potential as prognostic biomarkers in breast cancer.Bioinformatics advances · 2025Article
- Platelet-to-lymphocyte ratio as a prognostic biomarker in patients with human epidermal growth factor receptor 2-negative breast cancer undergoing taxane-carboplatin-based neoadjuvant chemotherapy.Therapeutic advances in medical oncology · 2025Article
- Diagnostic role of the neutrophil‑to‑lymphocyte ratio and the platelet‑to‑lymphocyte ratio in breast cancer: A systematic review and meta‑analysis.Oncology letters · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background & Objective: Female breast cancer is one of the most prevalent malignancies among women. The critical step in management of breast cancer is an accurate diagnosis. Hence, peripheral blood-based tests would be one of the most favorable and less invasive methods to study. Recent studies have investigated the inflammatory parameters such as neutrophil: lymphocyte ratio (NLR), the platelet: lymphocyte ratio (PLR), and the C-reactive protein (CRP) levels. The elevation in mentioned parameters was proposed as a key factor in cancer progression. The main goal of this study was to investigate the association of NLR, PLR, and CRP levels in patients with breast lesions. Methods: The NLR, PLR, and CRP levels were calculated from 200 female patients presenting with either benign or malignant lesions. Results: The cut-off values of NLR, PLR, and CRP were 1.24, 96, and 10.36 mg/L, respectively. A significant difference in NLR ( Conclusion: Elevated NLR, PLR, and CRP levels could predict the presence of malignancy. In addition to the low cost and properties of the mentioned methods, utilization of this data could facilitate and improve clinical decision-making for treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.